Evolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Albert G. White III acquired 20,000 shares of Evolus stock in a transaction dated Monday, June 9th. The stock was purchased at an average price of $9.45 per share, for a total transaction of $189,000.00. Following the completion of the acquisition, the director now directly owns 50,378 shares in the company, valued at approximately $476,072.10. This represents a 65.84% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Evolus Price Performance
Shares of NASDAQ:EOLS opened at $9.87 on Wednesday. The company's fifty day moving average price is $10.31 and its 200 day moving average price is $11.85. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm has a market capitalization of $636.38 million, a P/E ratio of -10.85 and a beta of 1.00.
Institutional Investors Weigh In On Evolus
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC purchased a new position in Evolus during the 1st quarter worth $39,000. State of Wyoming grew its position in Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after purchasing an additional 3,409 shares during the last quarter. KBC Group NV purchased a new position in Evolus during the 4th quarter worth $49,000. IFP Advisors Inc grew its position in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Evolus during the 4th quarter worth $106,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on EOLS. BTIG Research began coverage on shares of Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Barclays lifted their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus presently has a consensus rating of "Buy" and an average price target of $23.75.
View Our Latest Research Report on Evolus
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
